Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Oct 3, 2023 · TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. …

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, …

Jan 13, 2025 · The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.

TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 …

FEBRUARY 14, 2024 / 6:20PM, REGN.OQ - Regeneron Pharmaceuticals Inc at Oppenheimer Healthcare Life Sciences Conference So AD has, continues to be our largest overall …

Jun 9, 2023 · MAY 04, 2023 / 12:30PM, REGN.OQ - Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call We continue to invest in our research and development engine and expect it will …

OCTOBER 31, 2024 / 12:30PM, REGN.OQ - Q3 2024 Regeneron Pharmaceuticals Inc Earnings Call C O R P O R A T E P A R T I C I P A N T S Ryan Crowe Regeneron Pharmaceuticals Inc …

The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endpoint was met in the Phase 3 QUASAR …